Pharmacogenomics in cancer therapy: is host genome variability important?
Journal Article (Journal Article;Review)
Pharmacogenomics aims to elucidate the genomic determinants of drug disposition and effect. Because cancer chemotherapy is relatively nonspecific and has narrow therapeutic indices, there is great potential for pharmacogenomics to improve treatment outcomes by either reducing toxicity or increasing efficacy. The diversity of therapeutic targets for anticancer drugs and the intensity of clinical pharmacology research in oncology have provided many examples of clinically relevant pharmacogenomic applications. Important elements that are discussed in this article include the association of genetic variability in the metabolism, intracellular transport and targets of anticancer drugs. In addition, we summarize where the field stands currently, and how information from the host and tumor might be integrated into decision making.
Full Text
Duke Authors
Cited Authors
- Petros, WP; Evans, WE
Published Date
- September 2004
Published In
Volume / Issue
- 25 / 9
Start / End Page
- 457 - 464
PubMed ID
- 15559247
International Standard Serial Number (ISSN)
- 0165-6147
Digital Object Identifier (DOI)
- 10.1016/j.tips.2004.07.007
Language
- eng
Conference Location
- England